Dabigatran reversal agent: Rely on clinical judgment to start treatment

Sponsored by Boehringer Ingelheim Pty Ltd

Clinical judgment is the key to the appropriate use of idarucizumab (‘Praxbind’) to specifically reverse dabigatran in patients who need an urgent procedure or have serious bleeding, according to the lead author of the pivotal RE-VERSE AD study.1 Dr Charles Pollack, an emergency physician at Thomas Jefferson University Hospital in Philadelphia, told the limbic that ...

Already a member?

Login to keep reading.

© 2021 the limbic